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Interest in developing non invasive prenatal diagnosis techniques has grown within the past decade, especially since 
the discovery of cell-free fetal DNA (cffDNA) presence in maternal plasma in 1997.  
The potential use  of cffDNA presents two main limitations: the development of techniques to allow the distinction 
between maternal and fetal DNA, and the low presence of cffDNA in maternal plasma, that represents only 10-20% 
of the fraction. The use of epigenetic markers, which are sequences that contain covalent modifications of DNA that 
do not change the genome sequence and are stably transmitted during cell division, raised as a suitable choice.  
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Methodology 
Conduct a literature research using NCBI. 
Objectives  
Highlight the usefulness and importance of epigenetic markers for non-invasive 
prenatal testing.  
Describe the approaches and techniques used to perform the assays, its  
advantages, limitations and clinical applications.   
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Performed with methylation array analysis.  
 
 
 
 
 
 
 
 
 
 
Next generation sequencing  
References 
Ratio value calculation: 
 
                   Ratio =                            
 
 Genetic marker  unaffected by individual methylation variation   
  
         Ratio =  
 
Not depending on SNP heterogeneity 
Sex determination Rheshus D status  
[Epigenetic fetal marker] 
[Fetal-specific genetic marker] 
[Epigenetic fetal marker on the affected chromosome] 
[Epigenetic fetal marker on unaffected chromosome] 
Epigenetic-genetic chromoseme dosage 
Fetal-specific DNA methylation ratio 
Aneuploidies 
Multiple markers analyzed  
Similar to epigenetic-genetic chromosome dosage 
 
Discrimination value is achieved considering the discriminative 
coefficient for each marker:  
 
 
D = –6,331 + 0,959 XEP4 + 1,188 XEP5 + 0,424 XEP6 + 0,621 XEP7 
+ 0,028 XEP8 + 0,387 XEP10 – 0,683 XEP11 + 0,897 XEP12 
where XEPn = ratio value
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     Discussion 
- Epigenetic approaches have successfully defeated the restrictions that absolute discriminative genetic markers 
presented, allowing the application of non invasive diagnosis to all pregnancies by using universal fetal markers. 
- Clinical implementation of epigenetic approaches has to overcome a few limitations, since all the described  
techniques are useful but none of them are optimal. Even though, this techniques present more potential to be 
implemented on global scale than currently available sequencing procedures, because they are easier and less 
expensive to perform, and the necessary equipment is present in more laboratories. 
-  Further validation of potential epigenetic markers and improvement of ratio values should be performed.  
- The following years genome wide arrays will provide more differentially methylated regions that could be used 
as epigenetic biomarkers for other diseases, increasing its interest to be applied to clinics.  
Special consideration needs to be taken: 
- Methylation patterns are susceptible to external agents. 
- Methylation status can change depending on   
pregnancy state.  
- Individual methylation variation. 
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